Nancy Reau

Join me on January 13 for this upcoming @[AASLD Social Channel] webinar! Register for “Mid-career Muddle to Mid-career Magic: Making the Most of Midlife” online now at aasld.org/events-and-web…

A Practical Approach to the Diagnosis and Management of Hepatic Encephalopathy 🔖 @amjmed #LiverTwitter 👥@NancyReau David Bernstein @PaulYKwo Michelle Loftus @ann_MooreNP Sammy Saab 👉sciencedirect.com/science/articl…

24th #CuttackHepatitisSymposium to be organised on the eve of #WorldHepatitisDay at Mayfair Convention. Organised by @KGF_Trust and @AIIMSBhubaneswr Gastroenterology Dept. Key speakers include @wadhawan_manav @DrKaushalMadan1 @RoyAHep @PrajnaAnirvan @NancyReau #LiverTwitter

Insights into immune cells, checkpoint inhibitors, and personalized therapies (using RNA & microbiome analysis) are paving the way for better treatments for autoimmune liver diseases. 🚀 #LiverTwitter #Immunotherapy #PrecisionMedicine @JHepatology clinicalkey.com/#!/content/pla…

MetALD = The dangerous overlap of metabolic dysfunction + moderate alcohol use. Together, they speed up liver damage, inflammation, & cancer risk. A rising issue as metabolic disorders grow 🍷⚠️ nature.com/articles/s4435… #LiverTwitter #MetALD @RushDOIM

If you're looking for better sleep, a happy gut, and glowing skin, #DryJanuary might be for you. Additional side effects include a healthier heart, liver, and reduced cancer risk ;) @iamwellandgood wellandgood.com/dry-january-he… #livertwitter #MedTwitter #DryJanuaryChallenge

GLP-1s not only help with weight loss and blood sugar control but also seem to improve liver health. Data for GLP-1 receptor agonists in improving MASH pathology is encouraging. #livertwitter #MedTwitter @RushDOIM @Medscape medscape.com/viewarticle/wh…

🎇 Happy New Year! In 2024, I had many important conversations on personalized treatment strategies, monitoring, and new therapies for primary biliary cholangitis (PBC). Listen below! ⬇️ hcplive.com/authors/nancy-… #livertwitter #MedTwitter @RushDOIM @HCPLiveNews

So proud of our 3rd year fellow @ZoePostMD and transplant hepatology fellow @aryannasousaMD on their excellent presentations/arguments for the academic debate at The Liver Meeting! Great job! 👏🏻🤩 #TLM24 @AASLDtweets @AASLDFoundation

@AASLDtweets Vote Rush 💕

The Academic Debate is in full swing with plenty of laughs from a huge audience! #TLM24

#TLM2024 come cheer for team Rush!!

#aasld come cheer for team rush!

Immediately after seeing this poster at #TLM23, I asked @renumathyd if she would review benign liver lesions for @HepCommJournal She did. And the review is fantastic journals.lww.com/hepcomm/fullte… Authoritative, from a Master of all lesions in the liver

Thank you to everyone who attended #ACG2024! 📽️Enjoy "An #ACGfamily Home Movie: #ACG2024 Highlights" youtu.be/WTIn3bxyQtA?si… via @YouTube

The health of the liver is the topic of Dr. @MarkPochapin’s next segment of Chief’s Rounds via @SIRIUSXM live from #ACG2024 with ✅Dr. @NancyReau ✅Dr. @JasmohanBajaj ✅Dr. @AtoosaRabiee ✅Dr. #PaulMartin

🪩some glimpses of #ACG2024 Day 2️⃣ @AmCollegeGastro @ACG_EBGI

On September 13, an FDA Gastrointestinal Drug Advisory Committee voted that the benefits of obeticholic acid on clinical outcomes in patients with PBC could not be verified with available data. Learn about the potential implications: shorturl.at/a51c8 #livertwitter